Shares of the restaurant chain began trading at HK$7.19 per share, unchanged from the offer price, before plunging 7 per cent ...

Jiangsu Hengrui Pharmaceuticals, a leading Chinese developer of novel drugs that recently received approval to go public in ...

Pfizer and RemeGen's HER2 antibody-drug conjugate delivered positive phase 3 results in a bladder cancer trial in China. | ...

Chinese biotech company Bliss Biopharmaceutical (BlissBio) is reportedly considering a Hong Kong initial public offering (IPO ...

The China-based casual dining brand began trading its IPO after pricing its 168,364,000 shares at HKD 7.19 per share.

Trading in the shares is expected to start on May 23. Read more at straitstimes.com. Read more at straitstimes.com.

Chinese drug developer and producer Jiangsu Hengrui Pharmaceuticals is aiming to raise up to HK$9.89 billion ($1.27 billion) in a Hong Kong listing, according to a regulatory filing made on Thursday.

Hong Kong is calling for robotaxi operator Pony AI . The $6 billion Chinese company is exploring an offering in the city just ...

China’s Zijin Mining Group (OTCPK:ZIJMF) (OTCPK:ZIJMY) has picked Citic Securities Co. and Morgan Stanley (MS) to lead the ...

Chinese battery giant Contemporary Amperex Technology is planning to raise as much as US$4.0 billion in the year’s biggest ...

This digital payment services provider is likely to get a lift from China's initiatives to boost domestic consumption.

SINGAPORE] Companies have been flocking to file applications for initial public offerings (IPOs) in Hong Kong amid ...